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ABSTRACT The alarming diffusion of multidrug-resistant (MDR) bacterial strains re-
quires investigations on nonantibiotic therapies. Among such therapies, the use of
bacteriophages (phages) as antimicrobial agents, namely, phage therapy, is a prom-
ising treatment strategy supported by the ﬁndings of recent successful compassion-
ate treatments in Europe and the United States. In this work, we combined host
range and genomic information to design a 6-phage cocktail killing several clinical
strains of Pseudomonas aeruginosa, including those collected from Italian cystic ﬁbro-
sis (CF) patients, and analyzed the cocktail performance. We demonstrated that the
cocktail composed of four novel phages (PYO2, DEV, E215 and E217) and two previ-
ously characterized phages (PAK_P1 and PAK_P4) was able to lyse P. aeruginosa
both in planktonic liquid cultures and in bioﬁlms. In addition, we showed that the
phage cocktail could cure acute respiratory infection in mice and treat bacteremia in
wax moth (Galleria mellonella) larvae. Furthermore, administration of the cocktail to
larvae prior to bacterial infection provided prophylaxis. In this regard, the efﬁciency
of the phage cocktail was found to be unaffected by the MDR or mucoid phenotype
of the pseudomonal strain. The cocktail was found to be superior to the individual
phages in destroying bioﬁlms and providing a faster treatment in mice. We also
found the Galleria larva model to be cost-effective for testing the susceptibility of
clinical strains to phages, suggesting that it could be implemented in the frame of
developing personalized phage therapies.
KEYWORDS Galleria mellonella, Pseudomonas aeruginosa, bacteriophages, cystic
ﬁbrosis, phage therapy
The opportunistic pathogen Pseudomonas aeruginosa principally infects the airwaysof immunocompromised patients and is one of the principal bacteria isolated from
adults with cystic ﬁbrosis (CF). The appearance and diffusion of multidrug-resistant
(MDR) isolates of P. aeruginosa are responsible for the increasingly unsuccessful use of
antibiotics. Thus, alternative therapies are urgently needed, and the use of bacterio-
phages (phages), the natural viral enemies of bacteria, has received renewed attention
(1, 2). Phage therapy was proposed 100 years ago, before the discovery of antibiotics
(3). Following an initial worldwide expansion, the use of this therapy declined, being
replaced by the use of antibiotics, which were more successful. Beyond efﬁcacy itself,
the lack of precise knowledge of the complex interaction between phages and bacteria
has played a major role in the shift from using phages to using antibiotics. For instance,
while today genome sequencing and experimentation can determine whether a phage
is virulent or temperate, such information was not available in early 20th century.
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Temperate phages are known to serve as vehicles for bacterial sequence exchanges
between strains, eventually leading to the dissemination of genes coding for toxins or
antibiotic resistance. Therefore, for therapeutic applications, the use of only virulent
(strictly lytic) phages is advised. Compared to antibiotics, phages have several advan-
tages. First, as obligate bacterial viruses, they tend to be speciﬁc to their bacterial hosts
and their killing activity is conﬁned to a narrow range of pathogenic strains. This avoids
collateral damage to human and animal healthy commensal microbiota, contrary to
broad-spectrum antibiotics (4, 5). Another advantage of phage therapy over conven-
tional antibiotics is the dynamic dosing provided by phages, which multiply when the
target bacterial host strains are present and decrease in number as the target bacteria
are eliminated (6). Thus, phages provide an infection site-speciﬁc augmentation of the
dose that cannot be achieved through the standard repeated dosing of antibiotics. Lastly,
phages are often able to kill bacteria independently of their MDR phenotype (7, 8).
Several reports have demonstrated that the growth of a pathogenic bacterium can
be controlled in vitro and in vivo with speciﬁc phages. These range from the experi-
mental treatment of Escherichia coli diarrhea (9), Klebsiella pneumoniae pulmonary
infection (10), and Acinetobacter baumannii pneumonia (11) to that of P. aeruginosa
keratitis (12). In addition, the therapeutic effect of phage administration on P.
aeruginosa-infected mice (13–15) or Galleria larvae has also been reported (16). How-
ever, no consensual and validated guidelines for the selection of individual or multiple
therapeutic phages that target a speciﬁc pathogen have been adopted (17). One
strategy is to isolate the causative agent of the bacterial infection from the patient and
then identify in vitro one or more phages that lyse that strain(s). This approach is
laborious and time-consuming, and it also requires a large pool of phages to be on
hand. An alternative strategy would be to preemptively combine a mixture of phages
(cocktail) that together are able to efﬁciently kill a broad range of clinical strains of a
disease-speciﬁc pathogen (18).
In this study, we investigated the preemptive tactic, using in vitro and in silico criteria
to combine a mixture of phages to efﬁciently treat a broad range of P. aeruginosa
clinical strains isolated from Italian patients with CF. We show that a cocktail of six
phages virulent for Pseudomonas can kill with 77% coverage P. aeruginosa clinical
strains from CF patients, while it is effective at reducing pseudomonal bioﬁlms in vitro.
Furthermore, the phage cocktail resolved pseudomonal acute pneumonia in mice and
treated bacteremia in wax moth (Galleria mellonella) larvae.
RESULTS
Isolation and electron microscopy imaging of broad-host-range phages infect-
ing Italian P. aeruginosa strains isolated from cystic ﬁbrosis patients. We collected
40 P. aeruginosa strains from CF patients at several Italian medical centers (see Materials
and Methods). In addition, we added 2 Italian isolates from patients with chronic
obstructive pulmonary disease, 9 non-Italian clinical strains previously isolated from CF
and non-CF patients, 5 environmental isolates, and 2 laboratory strains (PAO1 and
PAO1 pilA) to increase the genetic diversity of the bacterial hosts tested (see Table S1
in the supplemental material).
Then, we isolated 23 novel phages as described in Materials and Methods (Table S2).
Next, we measured the efﬁciency of plating (EOP) of each phage on the panel of 58 P.
aeruginosa strains (Table S3). As expected, each phage had a distinct host range, with
no individual phage being able to lyse all strains in the aforementioned collection, and
some only lysed less than 30% of strains. Intriguingly, none of our tested phages was
able to lyse P. aeruginosa strains PaPh23 and PaPh30. However, about half of the
isolated phages exhibited a much broader host range by lysing more than half of the
strain collection.
From the pool of moderately broad host range phages, we selected six phages
(PYO2, E215, E220, S218, E217, and DEV) that, when combined, were theoretically
predicted to infect 97% of the strain collection (Table S3). Transmission electron
microscopy images of these phages are shown in Fig. S1. All belong to the order
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Caudovirales; PYO2, DEV and E220 are members of the Podoviridae family and share a
highly similar morphology (a regular icosahedral head of 72 nm in diameter and a short
tail of 18 nm); E215 and E217 belong to the Myoviridae family, and both share a very
similar morphology with a regular icosahedral head of 80 nm in diameter and a tail 185
nm long; S218 is a member of the Siphoviridae and possesses an icosahedral head of
100 nm in length and 60 nm in width and a ﬂexible 210-nm-long tail.
One-step growth experiments in PAO1 were performed in order to characterize the
PYO2, DEV, E215, and E217 phages (Fig. S2). Phages PYO2 and DEV have a similar latent
period (20 min) and burst size (100 and 200 PFU/ml, respectively), whereas E215 and
E217 show a longer latent period (30 to 40 min), and both have a burst size of over 200
PFU/ml.
Genome characterization of the selected phages. We sequenced phages PYO2,
E215, E220, S218, E217, and DEV, and their genomic characteristics are reported in Table
S4. The genomes of both phages PYO2 and DEV were 72,697 bp in length and 99%
similar. The alignments showed that the sequences of PYO2 and DEV are related to
those of the Podoviridae Lit1virus group and share similar levels of conservation with
the publically available sequences of Pseudomonas phages PEV2 and RWG. The ge-
nomes of phages E215 (66,789 bp) and E217 (66,291 bp) also had a high level of
similarity (97% identity over 98% of their length), are related to the genomes of
members of the P1virus subfamily of the Myoviridae, and closely resemble the genome
of Pseudomonas phage vB_PaeM_CEB_DP1.
In order to discard temperate phages and, more broadly, phages that could serve as
vehicles for undesirable functions, we searched for similarities between all putative viral
open reading frames (ORFs) and a custom database of genes expressing bacterial
virulence factors, antibiotic resistance, and integrases/excisionases/recombinases. We
found that the genomes of phages PYO2, DEV, E215, and E217 do not encode proteins
with similarity to undesirable functions, leading us to classify them as virulent. On the
contrary, as reported in Table S4, the genomes of phages E220 and S218 contained
open reading frames with high levels of similarity to genes annotated as integrases in
the ACLAME database (19). This suggests that phages E220 and S218 have a temperate
life cycle not conducive of a desirable antimicrobial agent and thus were not studied
further.
Evaluation of in vitro efﬁciency of transduction of the selected phages. We
tested the capacity of the PYO2, DEV, E215, and E217 phages to transduce genetic
markers. We found that the frequency of transduction was less than 109 per infecting
phage, a frequency that is about 100-fold lower than the typical general transduction
rate for virulent phages, leading us to conclude that these phages would unlikely serve
as vehicles to carry antibiotic resistance or virulence genes (20).
Deﬁnition of a genetically diverse phage cocktail. With the aim to assemble a
phage cocktail that displays a broad host range and genetic diversity, we selected 6
virulent phages, PYO2, DEV, E215, E217, PAK_P1, and PAK_P4. The last two are previ-
ously characterized P. aeruginosa Myoviridae virulent phages isolated in France (13, 21,
22) that are 93,198 bp and 93,147 bp, respectively, and that display 93% identity over
98% of their genome length. PYO2/DEV, E215/E217, and PAK_P1/PAK_P4 constitute
three groups of genomically similar phages and represent three viral genera. The six
phages do not show signiﬁcant sequence similarity to each other, other than the
sequence similarity between the pairs of closely related phages (Fig. S4 and Table S4).
Here, we refer to the mixture of all six phages as the “phage cocktail.”
In vitro characterization of the cocktail and its individual components. The EOP
of the cocktail was compared to that of each individual phage on 58 P. aeruginosa
strains and is reported in Table 1. As was to be expected, the phage cocktail was able
to lyse a range of bacterial strains broader than the range that any of the individual
phages that made up the cocktail could lyse. That is, a single phage with the broadest
host range lysed only 36 of the 58 strains in the full strain collection (62%) and 22 of
the 40 Italian CF clinical strains (55%), whereas combining the phages in a cocktail
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expanded the host range of the full strain collection lysed by 15% (45 out of 58 strains)
and the host range of the Italian CF clinical strain collection lysed by 20% (30 out of 40
strains). Of note, the host range of the phage cocktail in vitro was lower than that
predicted theoretically from summing the host range of each individual phage within
the cocktail. This phenomenon could be due to host infection competition between
phages (23, 24).
The lysis kinetics of P. aeruginosa strain PAO1 and PAK-lumi cultures infected with
each phage and with the cocktail were followed by monitoring the optical density (OD)
at 600 nm (OD600) over time (Fig. 1A to C). For PAO1, at a multiplicity of infection (MOI)
of 2.5, PYO2 and DEV caused a decrease in the OD600 at 1 to 1.5 h postinfection (p.i.)
and E215 caused a relatively smaller decrease at about 2 h. For PAK-lumi, the effect was
less pronounced both after DEV infection and after E215 infection. Interestingly, phage
E217 did not cause lysis but clearly stopped the growth of both PAO1 and PAK-lumi.
PAK_P1 and PAK_P4 did not alter PAO1 growth, whereas the OD600 of PAK-lumi started
to decrease at 2 h p.i.
After infection of both the PAO1 and PAK-lumi cultures with the phage cocktail (Fig.
2C), the OD600 decreased at about 70 min p.i. This indicates that the phages were able
to kill sensitive bacteria in vitro in a relatively short time after infection. After overnight
incubation, however, the OD600 reached high values, due to the growth of resistant
bacteria, as conﬁrmed by testing several bacteria (10/10 resistant clones), indicating
that the cocktail failed to prevent the outgrowth of phage-resistant variants.
Phages disrupt P. aeruginosa bioﬁlm. We tested the capability of phages to
reduce the bioﬁlms formed by green ﬂuorescent protein (GFP)-expressing P. aeruginosa
TABLE 1 Efﬁciency of plating of single phages selected for the cocktail and of the cocktaila
aFive microliters of 10-fold serial dilutions of the indicated single phages or of the phage cocktail was spotted on a lawn of each speciﬁc
bacterial host; the plates were observed after overnight incubation at 37°C. , EOP of 1; /, EOP of 101 to 102; /, EOP of 103;
, EOP of 104; T, turbid plaques.
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PAO1 or PAK-lumi strains. After 48 h of bioﬁlm formation on glass slides, the phages
were applied as a cocktail (Fig. 2A) or individually (Fig. S3). The bioﬁlm biomass nearly
disappeared after incubation with the phage cocktail. To quantify the bioﬁlm reduction,
we measured the bioﬁlm biomass by crystal violet staining of 24-h bioﬁlms and found
FIG 1 Growth kinetics of P. aeruginosa cells in liquid culture in the presence of phages. (A and B) Exponentially growing
bacteria (OD600  0.1) of either strain PAO1 (A) or strain PAK-lumi (B) were infected by the indicated phages, each at an
MOI of 2.5. For clarity, the results of only one out of three independent experiments are shown. The infection with E217
was repeated three times with each strain, with superimposable results. (C) PAO1 and PAK-lumi infection with the 6-phage
cocktail (CK; total MOI  2.5). The average and SD from two independent experiments are shown.
FIG 2 Disruption of the P. aeruginosa bioﬁlm by the phage cocktail. (A) Forty-eight-hour bioﬁlms of PAO1 gfp and PAK gfp without and after addition of the
6-phage cocktail (CK). (B) Twenty-four-hour bioﬁlms of the indicated P. aeruginosa strains were exposed for 4 h to the phage cocktail. The reduction of the
bioﬁlm biomass following treatment with the phage cocktail was compared with that following no treatment by measuring the OD600 after crystal violet
staining. The bioﬁlm reduction by the cocktail reached 62% for PAO1, 64% for PaPh5, 19% for AA43 (P  0.6), 37% for PaPh32, and 66% for PAK-lumi. The error
bars indicate standard deviations, and the statistical signiﬁcance of the bioﬁlm reduction (***, P  0.001) was assessed by Student’s t test.
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that the cocktail caused a signiﬁcant reduction in the PAO1 and PAK-lumi bioﬁlm
biomass (63% and 65%, respectively; Fig. 2B). In addition, the efﬁciency of the cocktail
in destroying a preformed bioﬁlm formed by various clinical P. aeruginosa strains was
also tested. The cocktail reduced 64% (P  0.001) of a highly dense bioﬁlm produced
by strain PaPh5 used in the ﬁrst infection and reduced the biomasses of the mucoid
AA43 strain and the mucoid MDR PaPh32 strain by 19% (P  0.6) and 37% (P  0.001),
respectively.
Intriguingly, PAK_P1 and PAK_P4, which are unable to replicate on PAO1, caused a
signiﬁcant increase in the PAO1 bioﬁlm biomass (Fig. S3). This effect was not observed
when the phages were components of the cocktail. Although the cause of this
phenomenon is unclear, it could be related to the host defense system to reduce phage
growth (25).
Phage treatment of P. aeruginosa respiratory infection in mice. We tested the
capacity of the phage cocktail to cure a P. aeruginosa acute respiratory infection in a
mouse model. Figure 3 shows that phage treatment even at the lowest MOI (an MOI of
0.05 for each phage) was effective at reducing the respiratory bacterial burden by 48 h
and achieving a 100% survival rate. Noninvasive longitudinal monitoring of P. aerugi-
nosa infection showed that the phage cocktail administered at each of the MOIs
tested led to a reduction of the bacterial burden in the mouse lungs (Fig. 3B). In
comparison, administration of the phage cocktail at the highest MOI (1.0) began to
reduce signiﬁcantly the bacterial density by 6 h posttreatment, whereas with
administration at the two lower MOIs (0.05 and 0.1), it took up to 9 h before the
reduction became signiﬁcant.
Phage treatment of P. aeruginosa systemic infection of G. mellonella larvae. In
the frame of developing personalized phage therapies before the treatment of patients,
we investigated the effects of the phages on P. aeruginosa clinical isolates in wax moth
(G. mellonella) larvae as a rapid and economical screening method. First, we assessed
that administration of the phage cocktail at the higher dose of an MOI of 25 (CK25) did
not per se cause adverse effects on the larvae (Fig. 4A and B). Then, we showed that
death was signiﬁcantly delayed in larvae infected with a lethal dose of PAK-lumi and
treated 1 h later with the phage cocktail (Fig. 4A). Indeed, the rate of survival of the
larvae after 20 h increased from about 17% to 49% by treatment with the cocktail at an
FIG 3 The phage cocktail fully cures acute respiratory infections in mice. (A) Fatal respiratory infections after 1  107 CFU
of P. aeruginosa strain PAK-lumi (PAK) (n 5 mice for each treatment group and n 3 for untreated mice) was intranasally
instilled into mice were cured by administration of the 6-phage cocktail (CK) at 2 h postinfection. The cocktail consisted
of a mixture of six Pseudomonas phages each given at an MOI of 0.05, 0.1, or 1.0 (CK0.05, CK0.1, and CK1.0, respectively).
(B) Photon emission of the chest area of infected mice quantiﬁed using an IVIS Spectrum 100 imaging system (p/sec/cm2/sr,
number of photons per second per square centimeter per steradian). The letters beside the data points indicate
signiﬁcance by two-way ANOVA with the Tukey correction, as follows: a, P  0.0012 for PAK versus PAKCK1.0; b, P 
0.0001 for PAK versus PAKCK1.0; c, P  0.0406 for PAKCK0.05 versus PAKCK1.0; d, P  0.0365 for PAKCK0.1 versus
PAKCK1.0; e, P  0.0003 for PAK versus PAKCK0.05; f, P  0.0008 for PAK versus PAKCK0.1; g, P  0.0001 for PAK
versus PAKCK1.0; h, P  0.0001 for PAK versus PAKCK0.05; i, P  0.0001 for PAK versus PAKCK0.1; and j, P  0.0001
for PAK versus PAKCK1.0.
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MOI of 8 (CK8) and to 63% by treatment with the cocktail at an MOI of 25 (CK25) (Fig.
4E). Even at a later time point (40 h), the rate of survival increased from 6.6% of larvae
not treated with phages to 26.6% and 30.5% (Mantel-Cox test, P  0.0001) of the
groups that received the phage cocktail at the different MOIs (Fig. 4A). Moreover, we
showed that pretreatment with the phage cocktail 1 h before PAK-lumi challenge
provided prophylaxis against lethal infection (Mantel-Cox test, P  0.0001) (Fig. 4B and
E). Interestingly, both of the two clinical strains PaPh5 and AA43 were also controlled
by the phage cocktail (P  0.0001) (Fig. 4C to E).
FIG 4 The phage cocktail prolongs the survival of systemically infected G. mellonella larvae. (A) Kaplan-Meier survival curves of
larvae infected with PAK-lumi (30 CFU/larva, n  45 per group) and treated 1 h after infection with PBS (PAK) or the 6-phage
cocktail (CK) at two different MOIs of 8 (PAKCK8) and 25 (PAKCK25). In addition, uninfected larvae received the cocktail at
an MOI of 25 (CK25). Pairwise comparisons between untreated infected larvae and phage-treated infected larvae using the
Mantel-Cox test indicated a signiﬁcant difference (P  0.0001 for both CK8 and CK25). (B) Kaplan-Meier survival curves of larvae
prophylactically treated at an MOI of 25 1 h before PAK-lumi challenge (CK25PAK) or PBS challenge (CK25) (n  20 per group).
Pairwise comparisons between untreated infected larvae and phage-treated infected larvae using the Mantel-Cox test indicated
a signiﬁcant difference (P  0.0001). (C and D) Kaplan-Meier survival curves of larvae infected with PaPh5 (30 CFU/larva) or AA43
(110 CFU/larva) (n  35 per group) and treated 1 h later with PBS (PaPh5 and AA43) or the 6-phage cocktail (PaPh5CK25 and
AA43CK25). Pairwise comparisons between untreated infected larvae and phage-treated infected larvae using the Mantel-Cox
test indicated a signiﬁcant difference (for PaPh5, P  0.0001; for AA43, P  0.0001). (E) Comparison of the rates of survival of
larvae treated with the phage cocktail at 20 h after infection with the indicated strains. Statistical signiﬁcance was assessed by
the chi-square test with the Yates correction when needed: PAK versus PAKCK8, P  0.01 (**); PAK versus PAKCK25, P 
0.0001 (***); PAK versus CKPAK, P  0.0001 (***); PaPh5 versus PaPh5CK, P  0.01 (**); and AA43 versus AA43CK, P  0.0001
(***).
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DISCUSSION
CF patients, who experience pulmonary infections predominantly caused by P.
aeruginosa, are increasingly exposed to the risk of infection caused by MDR strains due
to the recurrent use of antibiotics. In this study, we isolated and characterized new
phages, assembled a 6-phage cocktail, and tested its efﬁcacy against MDR P. aeruginosa
strains both in vitro and in two in vivo animal models.
Several studies have reported the successful treatment of experimental bacterial
infections with phages, supporting their use as ﬁrst-line therapy, in particular, for
infections caused by MDR pathogens (26–29). In line with these data, two compassion-
ate phage treatments were recently reported in Europe and the United States, con-
ﬁrming the efﬁcacy and safety of such an approach (30, 31). However, for these two
examples, the choice of phages was guided, ﬁrst, by their in vitro activity against the
patient’s pathogen without, to our knowledge, any in vivo validation step. In addition
to such a customized solution, a parallel strategy would be to design ready-to-use
cocktails with a broad host range. Here, we assembled a 6-phage cocktail, taking into
account the host range and genomic information for phages, and assessed its in vitro
and in vivo efﬁcacies.
The cocktail is made up of 3 pairs of closely related phages, as revealed by genome
sequencing (with divergences of less than 8% sequence identity between the compo-
nents of each pair). Although the pairs have highly similar genomes, the related phages
differ in their host range in vitro, which is part of the rationale for the construction of
the cocktail. For example, phage DEV lyses strain LESB58, whereas the closely related
phage PYO2 does not. The nucleotide sequences of these two phages, however, differ
by less than 1% over their complete genomes. We noticed that the genomic variation
is mainly conﬁned to two genes: the 3=-end region of the RNA polymerase gene (orf71
in Fig. S4B in the supplemental material), in which most substitutions observed were
synonymous, and the ORF encoding dUTPase (orf81 in Fig. S4B), in which 21/128 amino
acids (16%) differed. dUTPase has been reported to be essential for viral replication in
certain hosts (32) and implicated in the host range under speciﬁc conditions (33). Our
observations suggest that dUTPase genes can be considered attractive candidate
genes, beyond the expected structural genes involved in host recognition, for future
studies of host speciﬁcity mechanisms (34).
Compared to the host spectrum of the individual phages, our cocktail had in vitro
a broader host spectrum for clinically isolated P. aeruginosa strains. In addition, the
cocktail lysed all 3 MDR strains in our collection (strains PaPh24, PaPh25, and PaPh32),
implying that phage infection was independent of cells harboring an antibiotic resis-
tance mechanism. Moreover, the phage cocktail was able to infect and kill mucoid
strains isolated from chronically infected CF patients.
Treatment of a P. aeruginosa bioﬁlm with the phage cocktail demonstrated that
phages are able to enter the bioﬁlm, destroying the biomass and reaching the bacteria
embedded inside. In this respect, the use of the phage cocktail greatly increased the
effect of single-phage infections (compare Fig. 2 with Fig. S3). We also observed that
the phage cocktail reduced to different degrees the bioﬁlms formed by different strains,
which may have been due to the differences in bioﬁlm formation and the bioﬁlm
composition observed with clinical P. aeruginosa strains (35).
Our ﬁndings indicate that in mice, lethal acute respiratory infection can be cured by
treatment with the cocktail. Compared to our previous data obtained with a single
phage, the cocktail showed the advantage of having more rapid efﬁcacy in reducing
the bacterial load (13, 21). This suggests a synergistic action when using multiple
phages. Further investigations will be required to identify the mechanisms behind such
synergy, but in the light of the ﬁndings of our recent investigations on the role of the
immune system during monophage therapy, we can hypothesize that the cocktail
reduces the probability that phage-resistant bacteria will grow (15). In systemic G.
mellonella infection, in which bacteria were directly injected in the hemolymph, a
signiﬁcant delay in the time to death over that for the nontreated controls was
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observed upon phage injection. The presence of a signiﬁcant difference in lethality
between untreated and phage-treated larvae at an early time point after infection (20
h) suggests that this test could be introduced for in vivo evaluation of the effectiveness
of phage therapy. Moreover, the phage cocktail was able to prevent P. aeruginosa
infection in the larvae. Prophylaxis with phages could be proposed for CF or immuno-
compromised patients, who are frequently hospitalized and therefore at higher risk of
exposure to nosocomial infections. The use of the larva model provided several
advantages over the use of the murine model, among which was the ﬂexibility to test
many clinical strains, as shown here. Indeed, some P. aeruginosa clinical strains have
been found not to infect the respiratory tract of mice (36; unpublished data), which
limits the use of this model. Other advantages are related to the cost, the easy
management in a microbiology lab, and to some extent, the experimental time. These
characteristics of the larva model provide a solution for the in vivo evaluation of the
activities of phages and cocktails against a clinical isolate that could be integrated into
the process of selection of the phages best suited for use in the formulation of a
cocktail.
Overall, our strategy, based on (i) host range, (ii) genomic information, and (iii) in
vitro efﬁcacies, led to the formulation of a 6-phage cocktail that was validated in two
in vivo models. It should be noticed that the in vitro efﬁcacies in liquid cultures and
bioﬁlms were the less encouraging data, as the cocktail did not prevent within 24 h the
growth of bacterial resistant clones, and some individual phages enhanced the density
of bioﬁlms. Therefore, to design phage cocktails, the pertinence of in vitro tests under
conditions irrelevant to the treatment of human bacterial infections can be questioned,
despite its rationale being at the root of phage therapy (37).
MATERIALS AND METHODS
P. aeruginosa strains. Clinical isolates of P. aeruginosa were isolated from primary and chronically
infected patients at the Centro di Riferimento per la Fibrosi Cistica della Regione Lombardia, Milan, Italy,
and at the Ospedale Bambino Gesù, Rome, Italy, and kindly provided by A. Bragonzi of the Infection and
Cystic Fibrosis Unit at San Raffaele, Milan, Italy. Strain PAO1 pilA, in which the pilA gene has been deleted,
was kindly provided by F. Imperi (Università degli Studi di Roma-Sapienza, Rome, Italy). The other strains
were present in the lab collection. All the strains are listed in Table S1 in the supplemental material.
Strains PAO1 and PAK-lumi were transformed with plasmid tPUCP19-GFP (C. Penaranda and D. Hung,
personal communication), which expresses high levels of GFP to make them ﬂuorescent, and strain
PAO1Tcr (38) was used for transduction experiments.
Bacteriophage isolation. Our phage collection includes 25 independent isolates, listed in Table S2.
Several isolates originated from sewage samples collected from the Milano Nosedo and Milano Peschiera
Borromeo wastewater treatment plants. Independent samples collected on different days were used to
avoid the reisolation of the same phage. Clear plaques were puriﬁed by standard procedures (39). Two
phages were isolated from the commercial preparations Phagyo (batch number 06.06.13; JSC Biochim-
pharm, Tbilisi, Georgia) and Intesti Bacteriophage (batch number M2-501; Eliava Institute, Tbilisi, Georgia)
by plating the preparation on PAO1 and isolating a single clear plaque from each preparation. Several
natural derivatives of these two initial isolates with different plaque morphologies or host ranges were
added to the collection. On a few occasions, the evolution of some phage variants was performed, as
indicated previously (40), in which an exponential-phase culture of a speciﬁc strain was infected with a
phage and infection was continued for 24 h; then, the culture was centrifuged and the supernatant was
used to reinoculate a fresh bacterial culture. This procedure was repeated daily for 6 days. The EOP of
the evolved phage present after 6 days was compared to the EOP of the ancestral phage used as the
inoculum. If the EOP was improved, the phage was added to the collection. Despite several attempts, no
phage able to infect strains PaPh23 and PaPh30 was isolated.
High-titer phage stock preparations. High-titer preparations of the phages were obtained by
infection of 500 ml of liquid culture of PAO1 or PAK-lumi, as described in reference 21, with the following
modiﬁcations: the lysates were ﬁltered through 1.2-m-pore-diameter ﬁlters and incubated for 30 min
at 37°C with DNase (1 g/ml) and RNase (1 g/ml) before precipitation with polyethylene glycol. For in
vivo experiments, phage lysates were puriﬁed by cesium chloride ultracentrifugation, as described in
reference 41, and dialyzed against TN buffer (10 mM Tris, 150 mM NaCl, pH 7). Then, each phage
preparation was passed through an endotoxin removal column (EndoTrap HD; Hyglos, Germany) before
measuring the endotoxin level by Limulus amoebocyte lysate chromogenic endotoxin quantitation
(Pierce). The levels of endotoxins of the phage preparations were below the limit value recommended
for intravenous administration (5.0 international units/kg body mass/hour; http://www.who.int/
medicines/publications/pharmacopoeia/Bacterial-endotoxins_QAS11-452_FINAL_July12.pdf).
Plating efﬁciency. The plating efﬁciency of the isolated phages on clinical strains of P. aeruginosa
was determined according to standard protocols: 5 l of serial dilutions of a phage preparation was
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spotted on agar plates on which a speciﬁc bacterial host was spread. The number of plaques observed
after overnight incubation was compared to that obtained on strain PAO1 or PAK-lumi.
In vitro infection. For determining the lysis kinetics of infected cultures, a culture of strain PAO1 or
PAK-lumi in LD broth (42) at 37°C with shaking was infected with each phage at an OD600 of 0.1 or with
the 6-phage cocktail at an MOI of 2.5, and the OD of the culture was followed.
Sequencing and assembly of phage genome sequences and their screening for the presence of
potential undesirable gene products. Genomic DNA extracted from puriﬁed high-titer phage prepa-
rations was subjected to standard Illumina library preparation protocols and sequenced on an Illumina
Mi-Seq instrument at the CNR IBBIOM Institute in Bari, Italy, to generate paired-end (2 250 nucleotides)
sequence reads. Raw paired-end sequence data were subjected to stringent quality trimming and
removal of library adapters using Trimmomatic software (43) and assembled using the SPAdes (v3.7.1)
program (44) and k-mer lengths of 75, 97, and 119.
Each genome was assembled as a single contig and deposited in GenBank. BLAST similarity searches
of the complete genome sequences against the sequences in GenBank recovered high levels of identity
and contiguity with previously sequenced genomes and allowed taxonomic assignment of each isolate
(Table S4). An in-house database of undesirable genes was constructed by merging entries from the
ACLAME database of mobile elements (19) whose descriptions contained any of the terms “integrase,”
“excisionase,” “recombinase,” or “repressor” with those from the Comprehensive Antibiotic Resistance
Database (CARD) (45) and the Virulence Factor Database (VFDB) (46). All ORFs with the ATG, GTG, or TTG
start codon were inferred from viral genome sequences using a custom Python script and used as queries
for BLASTX (47) searches (E value cutoff, 5e04) against the undesirable gene database.
Transduction assay. Phages were tested for their ability to transduce the tetracycline resistance (Tcr)
marker from PAO1Tcr into wild-type PAO1. An aliquot (100 l) of a high-titer lysate (1  1010 PFU/ml)
obtained in PAO1TcR was used to infect a 10-ml overnight culture of the recipient strain PAO1. After static
incubation at room temperature for 30 min to allow phage adsorption, the tubes were transferred to
37°C for 20 min, the cells were centrifuged, and the pelleted cells were resuspended in 300 l LB.
Aliquots (150 l) of the cell mixture were spread onto two agar plates containing tetracycline (100 l/ml).
The frequency of transduction was calculated as the ratio of Tcr colony transductants to the adsorbed
phage.
Composition of the phage cocktail. Four newly isolated Pseudomonas phages that presented
different and complementary host ranges were selected as constituents of the phage cocktail. The four
newly isolated phages were named, according to a recent proposal for a rational scheme for the
nomenclature of viruses (48), vB_PaeP_PYO2, vB_PaeP_DEV, vB_PaeM_E215, and vB_PaeM_E217, abbre-
viated in this paper PYO2, DEV, E215, and E217, respectively.
To these, phages PAK_P1 and PAK_P4, previously characterized for their therapeutic efﬁcacies in
mouse infections (13, 21), were added; both are Myoviridae, have a head diameter of 80 nm and a tail
of about 130 nm, and share no homologies with the other 4 phages in the cocktail. Their genome
sequences (GenBank accession number NC_015294 and KC862300, respectively) are 93,198 bp and
93,147 bp, respectively, with 93% identity.
Our ﬁnal cocktail included these 6 phages: PYO2, DEV, E215, E217, PAK_P1, and PAK_P4. The cocktail
was composed of phages mixed at the same number of PFU per milliliter, and the cocktail was prepared
immediately before each experiment to ensure accurate phage titers.
Bioﬁlm disruption. Two methods were used to monitor bioﬁlm disruption: ﬂuorescence microscopy
and crystal violet staining. For better visualization of the bioﬁlms, we used either the PAK-lumi or PAO1
strain transformed with plasmid tPUCP19-GFP, which expresses a high level of GFP. Bioﬁlms of PAK gfp
and PAO1 gfp were grown in an 8-well chamber microscope slide (Nunc Lab-Tek chamber slide) for 48
h in 200 l LD broth (42) at 37°C. Every 24 h the supernatant was gently removed and replaced by fresh
LD broth. After 48 h, phages at 1  108 PFU/ml were added and incubation at 37°C was continued for
4 h. The supernatant containing the planktonic cells was removed, and the slide was gently washed and
examined with a Leica DMRB microscope equipped with standard ﬂuorescence ﬁlters using a 100
objective. Images were acquired with a charge-coupled-device video camera (Leica DCF 480).
For bioﬁlm evaluation by crystal violet staining, an overnight culture of either P. aeruginosa PAO1 or
a clinical isolate was diluted to an OD600 of about 0.02 in LD broth, and 100 l was inoculated into 96-well
polystyrene microtiter plates. The plates were incubated at 37°C for 24 h to allow bioﬁlm formation. Broth
containing planktonic cells was gently removed, the wells were washed with 200 l of LD, 120 l of LD
containing phage lysate at 108 PFU/ml was added, and incubation was continued for 4 h. After
incubation, the wells were carefully emptied and gently washed with H2O. The bacteria adhering to the
walls of the plate were stained with 150 l of 0.1% crystal violet solution in H2O for 20 min. After washing
with tap water, the dye was eluted from the adherent bioﬁlm with 150 l 5% SDS and quantiﬁed by
measuring the optical density of a 10-fold dilution of the eluate at 600 nm. Each treatment was repeated
in 18 wells, and the median value and standard deviation (SD) were calculated.
Animals and ethics. Mice were housed under pathogen-free conditions with ad libitum access to
food and water. Animal experiments were conducted in accordance with European directives on animal
protection and welfare and were approved by the French Ministry of Education and Research (reference
number 2015-0041) and the Institut Pasteur (reference number 10.565).
Mouse acute respiratory infection. Female BALB/c mice between 8 and 12 weeks of age were
anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine. Subsequently, the animals were intra-
nasally infected with 1  107 CFU mid-log-phase P. aeruginosa PAK-lumi suspended in 30 l phosphate-
buffered saline (PBS). After 2 h postinfection (p.i.), mice whose lungs were infected were treated
intranasally with the 6-phage cocktail at the indicated PFU dose suspended in 30 l PBS. An IVIS
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Spectrum 100 in vivo imaging system (PerkinElmer) was used to facilitate noninvasive longitudinal
monitoring of P. aeruginosa infection in live individual animals in real time, performed as previously
described (13, 49, 50).
Systemic infection of Galleria mellonella larvae. A PAK-lumi culture was grown to an OD600 of 0.5
in LD broth at 37°C with shaking, pelleted, and diluted to an OD of 1 in physiological solution, equivalent
to 1  109 CFU/ml. After appropriate dilution, 10 l of inoculum, containing about 30 cells of P.
aeruginosa PAK-lumi, was delivered into the larva hemolymph behind the last proleg. A phage suspen-
sion, consisting of 10 l containing the 6-phage cocktail at 1,500 or 4,500 PFU, was delivered behind the
last proleg on the opposite site at 1 h p.i. For prophylaxis experiments, the larvae were infected with the
phages 1 h before they were infected with the bacteria. All experiments used 15 or 20 larvae. A
positive-control group (larvae infected and treated with physiological solution) and two negative-control
groups (one group injected with physiological solution only and one group injected with the phage
suspension only to assess the toxicity of the phage cocktail) were also included. The larvae were placed
into petri dishes and incubated at 37°C in the dark. The survival of the larvae was followed hourly after
16 h p.i.; the larvae were recorded as dead when they did not move in response to touch.
Phage treatment of larvae infected with clinical P. aeruginosa strains was performed after determi-
nation of the lethal dose of bacteria of each strain, equal to 110 and 30 CFU/larva for the AA43 and PaPh5
strains, respectively. At 1 h after injection of the bacteria into the larvae, a ﬁxed dose of phage cocktail
(4,500 PFU/larva) was injected.
Statistical analysis. Statistical analysis was performed using Student’s t test or two-way analysis of
variance (ANOVA) with the Tukey test or the chi-square test with the Yates correction. P values for
Kaplan-Meier curves were calculated by the Mantel-Cox test. Statistical analysis was done using Graph-
Pad software (http://www.graphpad.com/quickcalcs/).
Accession number(s). The GenBank accession numbers for the phages are MF490236 for vB_PaeP_
PYO2, MF490238 for vB_PaeP_DEV, MF490241 for vB_PaeM_E215, MF490240 for vB_PaeM_E217,
MF490237 for vB_PaeP_E220, and MF490239 for vB_PaeS_S218.
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